Cel-Sci Corporation (CVM)

Cel-Sci Corporation reported a narrower loss for the first quarter of 2026 as the clinical-stage biotechnology company continues advancing its immunotherapy development program.

However, over the past month, CVS stock has risen by around 24%. That's thanks to a strong first-quarter earnings report, a turnaround in its worst-performing segment, and subsequent analyst upgrades.

Saudi 50/50 revenue deal and a 212-patient U.S. study define CEL-SCI’s quarter, while its CEO buys ~$930K of stock and plans to seek FDA accelerated approval.

To understand whether CVS Health stock might still offer value at around US$87.36, you need to know how that price compares with what the business could be worth using different valuation checks. Recent share price moves have been meaningful, with the stock showing returns of 4.9% over 7 days, ...

Shares of data protection software company Commvault (NASDAQ:CVLT) fell 4.3% in the afternoon session after the April PPI report sent Treasury yields to 10-month highs, with the 10-year yield rising to 4.49%.